| Expression pattern: |
UP |
| Associated gene: |
IGF2BP2, FGF9 mRNA |
| Associated microRNA: |
- |
| Biological function: |
Promotes cisplatin resistance by inducing tumor-associated macrophage polarization toward the M2 phenotype; promotes malignant progression (reduced apoptosis and increased proliferation markers under CDDP in vivo). |
| Molecular mechanism: |
circITGB6 acts as a scaffold to form a cytoplasmic RNA-protein ternary complex with IGF2BP2 and FGF9 mRNA, stabilizing FGF9 mRNA and increasing FGF9-dependent M2 macrophage polarization, which confers cisplatin resistance. |
| Biological pathway or process: |
macrophage polarization (promotes); immune regulation (promotes); drug resistance (promotes); mRNA stability (promotes) |
| Detected method: |
Q
H
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; ISH (In Situ Hybridization); Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Transfection; Colony Formation Assay; Annexin V/PI Flow Cytometry; IF (Immunofluorescence); In Vivo Animal Model; IHC (Immunohistochemistry); ELISA; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Western Blot; Flow Cytometry（Non-apoptosis/cycle）; Survival Analysis |
| Clinical significance: |
High circITGB6 is associated with cisplatin resistance and poor prognosis, and may serve as a prognostic marker and therapeutic target. |
| Description: |
circITGB6 (hsa_circ_0056856) is upregulated in cisplatin-resistant ovarian cancer tissues and serum and is associated with poor prognosis. It promotes cisplatin resistance by acting as a cytoplasmic scaffold to form a circITGB6/IGF2BP2/FGF9 RNA-protein ternary complex that stabilizes FGF9 mRNA, increasing FGF9-driven TAM polarization toward an M2 phenotype and thereby creating an immunosuppressive, chemoresistant microenvironment. |
| Confidence score: |
0.8747 |